OBJECTIVES: To assess the effectiveness of the newer antiepileptic drugs (AEDs)-in particular lamotrigine, topiramate, and levetiracetam-in controlling epileptic seizures in pregnant women. METHODS: Analysis of data in the Australian Register of Antiepileptic Drugs in Pregnancy concerning seizure control in 1,534 pregnancies in women with AED-treated epilepsies. RESULTS: In AED monotherapy (1,111 pregnancies), use of levetiracetam in pregnancies in the Australian Register was associated with levels of seizure control similar to those that applied for the major older AEDs carbamazepine and valproate, but with levels of seizure control superior to those associated with use of lamotrigine and topiramate. SIGNIFICANCE: Levetiracetam shows promise as a satisfactory drug for controlling seizures in pregnancy. Wiley Periodicals, Inc.
OBJECTIVES: To assess the effectiveness of the newer antiepileptic drugs (AEDs)-in particular lamotrigine, topiramate, and levetiracetam-in controlling epilepticseizures in pregnant women. METHODS: Analysis of data in the Australian Register of Antiepileptic Drugs in Pregnancy concerning seizure control in 1,534 pregnancies in women with AED-treated epilepsies. RESULTS: In AED monotherapy (1,111 pregnancies), use of levetiracetam in pregnancies in the Australian Register was associated with levels of seizure control similar to those that applied for the major older AEDs carbamazepine and valproate, but with levels of seizure control superior to those associated with use of lamotrigine and topiramate. SIGNIFICANCE: Levetiracetam shows promise as a satisfactory drug for controlling seizures in pregnancy. Wiley Periodicals, Inc.
Authors: Kimford J Meador; Page B Pennell; Ryan C May; Elizabeth Gerard; Laura Kalayjian; Naymee Velez-Ruiz; Patricia Penovich; Jennifer Cavitt; Jaqueline French; Sean Hwang; Alison M Pack; Maria Sam; Eugene Moore; Dominic M Ippolito Journal: Epilepsy Behav Date: 2018-05-03 Impact factor: 2.937
Authors: Kim Christian Danielsson; Nils Erik Gilhus; Ingrid Borthen; Rolv Terje Lie; Nils-Halvdan Morken Journal: PLoS One Date: 2019-11-25 Impact factor: 3.240